Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
External link for Servier Pharmaceuticals
200 Pier Four Boulevard
Boston , MA 02210, US
It’s great to see the team at #ASPHO26, the leading conference for the pediatric oncology community. If you’re in Minneapolis, stop by the booth to connect with the team!
Our team is excited to attend #ASPHO26 and to join the pediatric oncology community in discussing the latest innovations shaping pediatric drug development. Attending the meeting? Stop by booth 324 to connect with our team next week.
Last week, we celebrated Bring Your Child to Work Day with a full day of hands-on STEAM activities and learning! Supporting the families who make up our #Servier community is at the heart of our commitment to culture. We believe that by providing hands-on experiences, we can inspire children to see themselves as the scientists and leaders of tomorrow. Thank you to everyone who helped bring this exciting day to life! #BringYourChildToWorkDay #STEAM #STEAMEducation
Many rare neurological diseases are linked to well-characterized genetic drivers, opening the door to more targeted approaches. Among them, antisense oligonucleotides (ASOs) are gaining attention. By binding to faulty RNA, they can help prevent the production of harmful proteins, without directly altering the DNA itself. Exploring technologies like ASOs reflects a broader shift in how we approach innovation in neurology. At Servier, this means investing early, building dedicated expertise, and accelerating progress for patients with very limited options. Discover more about our work and the teams driving these efforts: https://lnkd.in/ecZ6gVrf #Research #Neurology #RareDisease
Today, we are pleased to welcome Day One Biopharmaceuticals to Servier. Together, we strengthen our shared ambition to advance innovative treatments for children and adults living with rare cancers, starting with pediatric low-grade glioma. By bringing together Servier US and Day One Biopharmaceuticals, we unite complementary scientific, clinical, and commercial strengths to continue to advance innovative oncology medicines for patients and families. We look forward to what we will build together. #RareCancers #PediatricCancer #PatientsFirst
Happy #AdministrativeProfessionalsDay to our incredible administrative team whose behind-the-scenes dedication keeps us running & drives us forward every day. Today and every day, we recognize the talent, professionalism, and unwavering support you bring to the teams across #Servier. Thank you for everything you do!
Today, we join the global community in recognizing AML World Awareness Day, honoring patients impacted by Acute Myeloid Leukemia (AML), a rare and aggressive #cancer of the blood and bone marrow. At Servier, this day serves as a powerful reminder of our ongoing mission: to raise awareness, share resources, and advocate for the patients we serve every day. Learn more about our efforts here: https://lnkd.in/e9dPrtUP #WorldAMLAwarenessDay #AcuteMyeloidLeukemia #AML
Today is a big day in our hometown! Good luck to all our Servier colleagues & friends running the Boston Marathon – we're cheering for you every step of the way. We're proud to call Boston home, a city defined by innovation, community, and determination. #BostonMarathon #BostonStrong
We’re looking forward to connecting with the global oncology community at this year’s #AACR Annual Meeting. Each year, this meeting reflects the collective progress driving cancer care forward. From groundbreaking research to transformative new therapies, we're excited to engage with the scientists and clinicians at the forefront of the fight against cancer. In #SanDiego this weekend? We hope to see you there!
Congratulations to Tinos Therapeutics, this year’s winner of Servier’s 2026 Golden Ticket to LabCentral! As a part of this year’s contest, they will benefit from the latest research equipment, shared infrastructure, and numerous programs and services offered by LabCentral. Our early-stage company experts will also be on hand to provide guidance and feedback. Learn more about Tinos Therapeutics and their research here: https://lnkd.in/e_xdg7Dc #Servier #LabCentral #GoldenTicket
Patient stories guide everything we do, particularly in the complex world of rare and ultra-rare neurological diseases. By partnering with patient advocacy groups (PAGs) throughout the R&D process, we're learning what matters most to patients and transforming our approach to neuroscience innovation: https://lnkd.in/dYqzBUrz #Patients #Research #Neurology